Benzinga's Top Upgrades, Downgrades For August 8, 2017

Loading...
Loading...

Top Upgrades

  • Citigroup upgraded United Parcel Service, Inc. UPS from Neutral to Buy. UPS shares rose 1.11 percent to $113.10 in pre-market trading.
  • Drexel Hamilton upgraded L3 Technologies Inc LLL from Hold to Buy. L3 Technologies shares rose 0.33 percent to close at $176.58 on Monday.
  • Analysts at Mitsubishi UFJ upgraded Twilio Inc TWLO from Neutral to Overweight. Twilio shares rose 14.3 percent to $34.90 in pre-market trading.
  • Analysts at Argus upgraded Tesla Inc TSLA from Hold to Buy. Tesla shares rose 0.57 percent to $357.20 in pre-market trading.
  • Morgan Stanley upgraded Foot Locker, Inc. FL from Equal-Weight to Overweight. Foot Locker shares gained 3.40 percent to $50.50 in pre-market trading.
  • Analysts at Pivotal Research upgraded Discovery Communications Inc. DISCA from Hold to Buy. Discovery shares gained 2.19 percent to close at $24.25 on Monday.
  • Analysts at Berenberg upgraded Cognizant Technology Solutions Corp CTSH from Hold to Buy. Cognizant shares fell 2.23 percent to close at $69.59 on Monday.
  • Susquehanna upgraded Rapid7 Inc RPD from Neutral to Positive. Rapid7 shares rose 7.57 percent to $16.20 in pre-market trading.
  • JP Morgan upgraded Varex Imaging Corp VREX from Underweight to Neutral. Varex Imaging shares rose 0.07 percent to close at $28.27 on Monday.


Top Downgrades

  • Baird downgraded Plains All American Pipeline, L.P. PAA from Outperform to Neutral. Plains All American shares fell 14.68 percent to $21.50 in pre-market trading.
  • Maxim Group downgraded GW Pharmaceuticals PLC- ADR GWPH from Buy to Hold. GW Pharmaceuticals shares fell 4.60 percent to $109.80 in pre-market trading.
  • Analysts at JP Morgan downgraded Diebold Nixdorf Inc DBD from Overweight to Neutral. Diebold shares fell 0.89 percent to close at $22.35 on Monday.
  • Wedbush downgraded Beazer Homes USA, Inc. BZH from Outperform to Neutral. Beazer Homes shares rose 4.08 percent to close at $16.08 on Monday.
  • H.C. Wainwright downgraded Zynerba Pharmaceuticals Inc ZYNE from Buy to Neutral. Zynerba Pharmaceuticals shares declined 3.75 percent to $6.42 in pre-market trading.
  • Analysts at Jefferies downgraded NxStage Medical, Inc. NXTM from Buy to Hold. NxStage Medical shares fell 0.40 percent to $29.55 in pre-market trading.
  • Janney Capital downgraded Depomed Inc DEPO from Buy to Neutral. Depomed shares dropped 17.66 percent to $7.60 in pre-market trading.
  • SunTrust Robinson Humphrey downgraded National-Oilwell Varco, Inc. NOV from Hold to Sell. National Oilwell Varco shares declined 4.19 percent to close at $31.79 on Monday.
  • Deutsche Bank downgraded THL Credit, Inc. TCRD from Buy to Hold. THL Credit shares fell 1.22 percent to $9.75 in pre-market trading.


Top Initiations

  • Analysts at Morgan Stanley initiated coverage on Lockheed Martin Corporation LMT with an Overweight rating. The price target for Lockheed Martin is set to $342. Lockheed Martin shares closed at $297.15 on Monday.
  • Cowen & Co. initiated coverage on Akcea Therapeutics Inc AKCA with an Outperform rating. Akcea Therapeutics shares closed at $14.90 on Monday.
  • DA Davidson initiated coverage of Broadridge Financial Solutions, Inc. BR with a Neutral rating. The price target for Broadridge Financial is set to $74. Broadridge Financial shares closed at $75.60 on Monday.
  • Morgan Stanley initiated coverage on General Dynamics Corporation GD with an Underweight rating. The price target for General Dynamics is set to $185. General Dynamics shares closed at $201.14 on Monday.
  • Barclays initiated coverage on Brighthouse Financial Inc BHF with an Overweight rating. The price target for Brighthouse Financial is set to $72. Brighthouse Financial shares closed at $61.72 on Monday.
  • Analysts at Morgan Stanley initiated coverage on Northrop Grumman Corporation NOC with an Equal-Weight rating. The price target for Northrop Grumman is set to $279. Northrop Grumman shares closed at $269.58 on Monday.
  • Analysts at Stifel Nicolaus initiated coverage on Akcea Therapeutics Inc AKCA with a Buy rating. The price target for Akcea Therapeutics is set to $19. Akcea Therapeutics shares closed at $14.90 on Monday.
Loading...
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: UpgradesDowngradesInitiationAnalyst RatingsAerospace & DefenseDowngradesIndustrialsInitiationstop upgrades
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...